The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,002
Context-dependent actions of Polycomb repressors in cancer
Koppens, M. A. J., & van Lohuizen, M. (2015) · Oncogene · doi:10.1038/onc.2015.195 · Cited by 88
Garrett, M. C., Sperry, J., Braas, D., Yan, W., Le, T. M., Mottahedeh, J., Ludwig, K., Eskin, A., Qin, Y., Levy, R., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0177-4 · Cited by 86
Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
Chai, R., Li, G., Liu, Y., Zhang, K., Zhao, Z., Wu, F., Chang, Y., Pang, B., Li, J., Li, Y., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0179 · Cited by 87
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 92
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A., Abbas, S., Kim, S., Ortega, M. M., Bouamar, H., Escobedo, Y. A., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 88
Boutzen, H., Saland, E., Larrue, C., de Toni, F., Gales, L., Castelli, F. A., Cathebas, M., Zaghdoudi, S., Stuani, L., Kaoma, T., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150736 · Cited by 92
Updates in prognostic markers for gliomas
Aquilanti, E., Miller, J. J., Santagata, S., Cahill, D. P., & Brastianos, P. K. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy158 · Cited by 88
Epigenetic Deregulation of Apoptosis in Cancers
Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 94
A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery
Tan, Y. Q., Zhang, S., Wei, J., Dong, D., Wang, X., Yang, G., Tian, J., & Zhang, H. (2019) · European Radiology · doi:10.1007/s00330-019-06056-4 · Cited by 83
Friend or foe—IDH1 mutations in glioma 10 years on
Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 84
Molecular analysis of diffuse intrinsic brainstem gliomas in adults
Reyes-Botero, G., Giry, M., Mokhtari, K., Labussière, M., Idbaïh, A., Delattre, J., Laigle–Donadey, F., & Sanson, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1312-2 · Cited by 90
Mukherjee, J., Johannessen, T.-C. A., Ohba, S., Chow, T. T., Jones, L. E., Pandita, A., & Pieper, R. O. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2269 · Cited by 87
Badur, M. G., Muthusamy, T., Parker, S. J., Ma, S., McBrayer, S. K., Cordes, T., Magaña, J. H., Guan, K., & Metallo, C. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.074 · Cited by 87
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 90
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 91
IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 88
Self-citationMangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 89
Yang, Z., Jones, A., Widschwendter, M., & Teschendorff, A. E. (2015) · Genome biology · doi:10.1186/s13059-015-0699-9 · Cited by 83
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
D-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 87
Ohba, S., Mukherjee, J., See, W. L., & Pieper, R. O. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0924 · Cited by 84
Metabolic Reprogramming in Mutant IDH1 Glioma Cells
Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 90
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Loebel, F., Paschereit, F., Heppner, F. L., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0745-z · Cited by 81
Novel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 82
Molecular and Circulating Biomarkers of Brain Tumors
Jelski, W., & Mroczko, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137039 · Cited by 82
Distinct metabolic hallmarks of WHO classified adult glioma subtypes
Björkblom, B., Wibom, C., Eriksson, M., Bergenheim, A. T., Sjöberg, R. L., Jonsson, P., Brännström, T., Antti, H., Sandström, M., & Melin, B. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac042 · Cited by 78
Geisenberger, C., Möck, A., Warta, R., Rapp, C., Schwager, C., Korshunov, A., Nied, A.-K., Capper, D., Brors, B., Jungk, C., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1427-y · Cited by 78
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
DNA methylation-based reclassification of olfactory neuroblastoma
Capper, D., Engel, N. W., Stichel, D., Lechner, M., Glöß, S., Schmid, S., Koelsche, C., Schrimpf, D., Niesen, J., Wefers, A. K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1854-7 · Cited by 80
Cancer: pathological nuclear reprogramming?
Goding, C. R., Pei, D., & Lü, X. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3781 · Cited by 82
The genetic landscape of anaplastic astrocytoma
Killela, P. J., Pirozzi, C. J., Reitman, Z. J., Jones, S., Rasheed, B. A., Lipp, E., Friedman, H. S., Friedman, A. H., He, Y., McLendon, R. E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1505 · Cited by 80
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
Jalbert, L. E., Elkhaled, A., Phillips, J. J., Neill, E., Williams, A. A., Crane, J. C., Olson, M. P., Molinaro, A. M., Berger, M. S., Kurhanewicz, J. V., et al. (2017) · Scientific Reports · doi:10.1038/srep44792 · Cited by 80
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino, M., Kurz, S. C., Chiriboga, L. A., Serrano, J., Zeck, B., Sen, N., Patel, S. V., Shen, G., Vasudevaraja, V., Tsirigos, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2312 · Cited by 80
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
Wu, F., Jiang, H., Zheng, B., Kogiso, M., Yao, Y., Zhou, C., Li, X., & Song, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00684 · Cited by 78
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 80
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Stadlbauer, A., Zimmermann, M., Kitzwögerer, M., Oberndorfer, S., Rössler, K., Dörfler, A., Buchfelder, M., & Heinz‐Peer, G. (2016) · Radiology · doi:10.1148/radiol.2016161422 · Cited by 78
Zeng, A., Hu, Q., Liu, Y., Wang, Z., Cui, X., Li, R., Yan, W., & You, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4920 · Cited by 77
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
Fons, N. R., Sundaram, R. K., Breuer, G. A., Peng, S., McLean, R. L., Kalathil, A., Schmidt, M. S., Carvalho, D. M., Mackay, A. G., Jones, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11732-6 · Cited by 77
Unique biology of gliomas: challenges and opportunities
Watkins, S., & Sontheimer, H. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.05.001 · Cited by 76
Chromatin-modifying agents in anti-cancer therapy
Seidel, C., Florean, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.012 · Cited by 79
Carella, A., Tejedor, J. R., García, M. G., Urdinguio, R. G., Bayón, G. F., Sierra, M., López, V., Toraño, E. G., Santamarina‐Ojeda, P., Pérez, R. F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32520 · Cited by 77
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Xia, L., Wu, B., Fu, Z., Fěng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4008 · Cited by 80
Emerging circulating biomarkers in glioblastoma: promises and challenges
Touat, M., Durán-Peña, A., Alentorn, A., Lacroix, L., Massard, C., & Idbaïh, A. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1087315 · Cited by 77
Current State and Future Prospects of Immunotherapy for Glioma
Kamran, N., Alghamri, M. S., Núñez, F. J., Shah, D., Asad, A. S., Candolfi, M., Altshuler, D. B., Lowenstein, P. R., & Castro, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0122 · Cited by 77
Sulfur metabolism and its contribution to malignancy
Ward, N. P., & DeNicola, G. M. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.05.001 · Cited by 74
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Zheng, B., Yao, Y., Liu, Z., Deng, L., Anglin, J. L., Jiang, H., Prasad, B. V. V., & Song, Y. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400036z · Cited by 76
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1
Cahill, D. P., Louis, D. N., & Cairncross, J. G. (2015) · CNS Oncology · doi:10.2217/cns.15.32 · Cited by 77
OH, the Places You’ll Go! Hydroxylation, Gene Expression, and Cancer
Ploumakis, A., & Coleman, M. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.026 · Cited by 77
Cai, J., Yang, P., Zhang, C., Zhang, W., Liu, Y., Bao, Z., Liu, X., Du, W., Wang, H., Jiang, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1838 · Cited by 76
Dąbrowski, M. J., & Wojtaś, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143478 · Cited by 73
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
Qu, J., Sun, W., Zhong, J., Lv, H., Zhu, M., Xu, J., Jin, N., Xie, Z., Tan, M., Lin, S., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201607008 · Cited by 74
Zhou, L., Wang, Z., Hu, C., Zhang, C., Kovatcheva‐Datchary, P., Yu, D., Liu, S., Ren, F., Wang, X., Li, Y., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00663 · Cited by 73
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 76
Namba-Fukuyo, H., Funata, S., Matsusaka, K., Fukuyo, M., Rahmutulla, B., Mano, Y., Fukayama, M., Aburatani, H., & Kaneda, A. (2016) · Oncotarget · doi:10.18632/oncotarget.13130 · Cited by 74
Han, J., & Puri, R. K. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2680-9 · Cited by 73
Turcan, Ş., & Cahill, D. P. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620238 · Cited by 73
Molecular profiling of long-term IDH-wildtype glioblastoma survivors
Burgenske, D. M., Yang, J., Decker, P. A., Kollmeyer, T. M., Kosel, M., Mladek, A. C., Caron, A. A., Vaubel, R. A., Gupta, S. K., Kitange, G. J., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz129 · Cited by 73
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 75
Kitange, G. J., Mladek, A. C., Schroeder, M. A., Pokorny, J. C., Carlson, B. L., Zhang, Y., Nair, A., Lee, J., Yan, H., Decker, P. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.045 · Cited by 73
Schenkel, L. C., Kernohan, K. D., McBride, A., Ditta, R., Hodge, A., Ainsworth, P., Rodenhiser, D. I., Paré, G., Bérubé, N. G., Skinner, C. D., et al. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0118-4 · Cited by 74
Yamashita, A. S., Rosa, M. D. C., Borodovsky, A., Festuccia, W. T., Chan, T. A.-T., & Riggins, G. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy146 · Cited by 73
Self-citationTumor Metabolism of Malignant Gliomas
Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 73
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 73
Xu, H., Sun, Y., You, B., Huang, C., Ye, D., & Chang, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.014 · Cited by 72
Kurek, K. C., Pansuriya, T. C., van Ruler, M. A. J. H., van den Akker, B., Luks, V. L., Verbeke, S., Kozakewich, H. P., Sciot, R., Lev, D. C., Lazar, A. J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.012 · Cited by 73
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 73
The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma
Huse, J. T., & Aldape, K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0831 · Cited by 69
Self-citationThe association between copy number aberration, DNA methylation and gene expression in tumor samples
Sun, W., Bunn, P., Jin, C., Little, P., Zhabotynsky, V., Perou, C. M., Hayes, D. N., Chen, M., & Lin, D.-Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky131 · Cited by 70
Deletion of the Mitochondrial Chaperone TRAP-1 Uncovers Global Reprogramming of Metabolic Networks
Lisanti, S., Tavecchio, M., Chae, Y. C., Liu, Q., Brice, A. K., Thakur, M. L., Languino, L. R., & Altieri, D. C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.061 · Cited by 69
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.008 · Cited by 69
Röver, L. K., Gevensleben, H., Dietrich, J., Bootz, F., Landsberg, J., Goltz, D., & Dietrich, D. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.016 · Cited by 73
Gorlia, T., Delattre, J., Brandes, A. A., Kros, J. M., TAPHOORN, M. J. B., Kouwenhoven, M. C. M., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Lacombe, D. A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.039 · Cited by 70
IDH1: Linking Metabolism and Epigenetics
Raineri, S., & Mellor, J. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00493 · Cited by 70
The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen
Malta, T. M., Sabedot, T. S., Morosini, N. S., Datta, I., Garofano, L., Vallentgoed, W., Varn, F. S., Aldape, K., D'Angelo, F., Bakas, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2093 · Cited by 68
Self-citationInterlaboratory comparison of IDH mutation detection
van den Bent, M. J., Hartmann, C. J., Preusser, M., Ströbel, T., Dubbink, H. J., Kros, J. M., von Deimling, A., Boisselier, B., Sanson, M., Halling, K. C., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1056-z · Cited by 68
Making it or breaking it: DNA methylation and genome integrity
Sriraman, A., Debnath, T. K., Xhemalçe, B., & Miller, K. M. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200009 · Cited by 69
Miller, J. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01238-3 · Cited by 70
Adult type diffuse gliomas in the new 2021 WHO Classification
Antonelli, M., & Poliani, P. L. (2022) · Pathologica · doi:10.32074/1591-951x-823 · Cited by 72
Brennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.025 · Cited by 67
Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70
Molecular pathogenesis of intrahepatic cholangiocarcinoma
Andersen, J. B. (2014) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.155 · Cited by 68
MiR-181a regulates lipid metabolism via IDH1
Chu, B., Wu, T. H., Miao, L., Mei, Y., & Wu, M. (2015) · Scientific Reports · doi:10.1038/srep08801 · Cited by 68
Chaumeil, M. M., Radoul, M., Najac, C., Eriksson, P., Viswanath, P., Blough, M. D., Chesnelong, C., Luchman, H. A., Cairncross, J. G., & Ronen, S. M. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.06.018 · Cited by 67
DNA-Methylation: Master or Slave of Neural Fate Decisions?
Stricker, S. H., & Götz, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00005 · Cited by 66
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 69
Choi, J., Kim, S. H., Ahn, S. S., Choi, H. J., Yoon, H. I., Cho, J., Roh, T. H., Kang, S., Chang, J. H., & Suh, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59089-x · Cited by 67
Duchmann, M., Micol, J., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J., Braun, T., Adès, L., Chantepie, S., Lemasle, É., et al. (2021) · Blood · doi:10.1182/blood.2020010165 · Cited by 66
Compendium of aberrant DNA methylation and histone modifications in cancer
Hattori, N., & Ushijima, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.140 · Cited by 72
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 71
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Staniszewska, A. D., Pilger, D., Gill, S. J., Jamal, K., Bohin, N., Guzzetti, S., Gordon, J. A., Hamm, G. R., Mundin, G., Illuzzi, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2094 · Cited by 66
Long, P. M., Moffett, J. R., Namboodiri, A. M. A., Viapiano, M. S., Lawler, S. E., & Jaworski, D. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.487553 · Cited by 65
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 69
Ogura, R., Tsukamoto, Y., Natsumeda, M., Isogawa, M., Aoki, H., Kobayashi, T., Yoshida, S., Okamoto, K., Takahashi, H., Fujii, Y., et al. (2015) · Neuropathology · doi:10.1111/neup.12196 · Cited by 64
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
